Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.08) by 1.85 percent. This is a 11.58 percent decrease over losses of $(0.95) per share from the same period last year.